TVM, which has a wide range of products in ophthalmology, neurology, geriatrics, gastroenterology, anti-poison management and health and wellness, says that the acquisition is designed to boost the company's international scope, building market share and expanding its leadership in the fields of ophthalmology and neurology beyond France.
The acquisition will also strengthen TVM’s position in the area of animal anti-poison treatment as Forum Animal Health already supplies a canine emetic which it has been marketing in the UK for three years with an awareness campaign about the dangers of toxic products to dogs. This, the company says, has contributed to a significant increase in early interventions by veterinary surgeons in cases of poisoning. A similar campaign is currently being led in France by the TVM laboratory.
To accompany the change, Forum Animal Health is adopting a new visual identity, shown above right.
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.